Travere Therapeutics Stock Today
| TVTX Stock | USD 18.18 0.07 0.38% |
Performance20 of 100
| Odds Of DistressLess than 47
|
Travere Therapeutics is trading at 18.18 as of the 26th of November 2024; that is 0.38 percent decrease since the beginning of the trading day. The stock's open price was 18.25. Travere Therapeutics has 47 percent odds of going through some form of financial distress in the next two years but had a very solid returns during the last 90 days. Equity ratings for Travere Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of November 2012 | Category Healthcare | Classification Health Care |
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. The company has 87.03 M outstanding shares of which 7.99 M shares are at this time shorted by private and institutional investors with about 3.92 trading days to cover. More on Travere Therapeutics
Moving together with Travere Stock
Moving against Travere Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Travere Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Eric Dube | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTravere Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Travere Therapeutics' financial leverage. It provides some insight into what part of Travere Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Travere Therapeutics (TVTX) is traded on NASDAQ Exchange in USA. It is located in 3611 Valley Centre Drive, San Diego, CA, United States, 92130 and employs 380 people. Travere Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.59 B. Travere Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 87.03 M outstanding shares of which 7.99 M shares are at this time shorted by private and institutional investors with about 3.92 trading days to cover.
Travere Therapeutics currently holds about 553.17 M in cash with (280.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65.
Check Travere Therapeutics Probability Of Bankruptcy
Ownership AllocationTravere Therapeutics shows a total of 87.03 Million outstanding shares. The majority of Travere Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Travere Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Travere Therapeutics. Please pay attention to any change in the institutional holdings of Travere Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Travere Ownership Details
Travere Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2024-09-30 | 1.8 M | |
| Finepoint Capital Lp | 2024-06-30 | 1.8 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.7 M | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.6 M | |
| Assenagon Asset Management Sa | 2024-09-30 | 1.4 M | |
| Kynam Capital Management, Lp | 2024-09-30 | 1.4 M | |
| Balyasny Asset Management Llc | 2024-09-30 | 1.3 M | |
| Woodline Partners Lp | 2024-06-30 | 1.3 M | |
| Emerald Mutual Fund Advisers Trust | 2024-09-30 | 1.2 M | |
| Armistice Capital, Llc | 2024-09-30 | 7.6 M | |
| Blackrock Inc | 2024-06-30 | 7.6 M |
Travere Therapeutics Historical Income Statement
Travere Stock Against Markets
Travere Therapeutics Corporate Management
| Elizabeth JD | General VP | Profile | |
| Elizabeth Reed | General VP | Profile | |
| William Rote | Senior Development | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Angela Giannantonio | Senior Resources | Profile | |
| Jula MD | Chief Officer | Profile | |
| Casey Logan | Chief Officer | Profile |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.